Product Document Searching Made Easy by 2D Code! | TCI Chemistry News July 2026 | [Product Highlights] Chain Transfer Agents for Cationic RAFT... | Various analytical charts can be searched on each product detail page and Product Document Search (The kinds of analytical charts differ by product)
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 155648-60-5 | Product Number: M2360
Minodronate Monohydrate
×
Purity: >98.0%(HPLC)
Synonyms:
- 1-Hydroxy-2-[imidazo[1,2-a]pyridin-3-yl]ethylidene-1,1-diphosphonic Acid Monohydrate
- Minodronic Acid Monohydrate
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
|
|---|---|---|---|---|---|
| 25MG |
$226.00
|
29 | 10 | It can be shipped in about 2 weeks after ordering |
* Please contact our distributors or
TCI
to order our products. The above prices do not include freight cost, customs, and other charges to the destination.
* The storage conditions are subject to change without notice.
| Product Number | M2360 |
Purity / Analysis Method 
|
>98.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__9H__1__2N__2O__7P__2·H__2O = 340.17 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature
|
Room Temperature (Recommended in a cool and dark place, <15°C) |
| Packaging and Container
|
25MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 155648-60-5 |
| Related CAS RN
|
180064-38-4 |
| Reaxys Registry Number | 19668048 |
| PubChem Substance ID | 253660080 |
| MDL Number | MFCD00890772 |
Specifications
| Appearance | White to Light yellow to Light red powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| NMR | confirm to structure |
Properties (reference)
| Solubility in water | Insoluble |
GHS
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H301 : Toxic if swallowed. H361 : Suspected of damaging fertility or the unborn child. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P301 + P310 + P330 : IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth. P405 : Store locked up. |
Related Laws:
| RTECS# | SZ8562470 |
Transport Information:
| UN Number | UN2811 |
| Class | 6.1 |
| Packing Group | III |
| H.S.code* | 2933.99-000 |
Application
Bone Resorption Inhibitor
Bisphosphonates (BPs), including minodronate, ibandronate, etc., are very effective inhibitors of bone resorption in vivo and in vitro. Minodronate monohydrate (1) is one of BPs.1,2) These compounds are characterized by two C-P bonds which are located on the same carbon atom, i.e. geminal BPs, and have been used for many research studies regarding bone metabolism.1,2)
According to differences in the side chain, BPs can be divided into two groups, non-nitrogen containing BPs (non-N-BPs) and nitrogen-containing BPs (N-BPs). 1 is a N-BP and is classified as a third-generation heterocyclic N-BP.2,3) N-BPs inhibit farnesyl pyrophosphate synthetase, a key enzyme in the mevalonate pathway, which affects cellular activity and survival.1,2) Regarding inhibition of bone resorption, 1, as well as zoledronic acid, is more effective than other BPs.4)
According to differences in the side chain, BPs can be divided into two groups, non-nitrogen containing BPs (non-N-BPs) and nitrogen-containing BPs (N-BPs). 1 is a N-BP and is classified as a third-generation heterocyclic N-BP.2,3) N-BPs inhibit farnesyl pyrophosphate synthetase, a key enzyme in the mevalonate pathway, which affects cellular activity and survival.1,2) Regarding inhibition of bone resorption, 1, as well as zoledronic acid, is more effective than other BPs.4)
References
- 1)Bisphosphonates from bench to bedside
- 2)Computational insights into binding of bisphosphonates to farnesyl pyrophosphate synthase
- 3)A review of minodronic acid hydrate for the treatment of osteoporosis
- 4) Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates
PubMed Literature
Documents
Product Documents (Note: Some products will not have analytical charts available.)
Enter TCI Product Number
Enter KISHIDA Product Number
4-5 alphanumeric characters before the hyphen
7 alphanumeric characters
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
• The requested SDS is not available.
Specifications
The requested specifications are not available.
Please Contact Us for more information.
The requested specifications are not available.
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Incorrect Lot Number. Please input only the 7 alphanumeric characters.
• Please check that the lot number you have entered is correct. It is 4-5 alphanumeric characters before the hyphen. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
• If your information is correct and you are still not able to view the requested certificates, Please Contact Us for more information.
• Please check that the lot number you have entered is correct. It is 7 alphanumeric characters. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Incorrect Lot Number. Please input only the 7 alphanumeric characters.
The requested analytical chart is not available. Sorry for the inconvenience.